You are here
P2D, INC
UEI: KX3EAX2JEMV8
# of Employees: 2
HUBZone Owned: No
Socially and Economically Disadvantaged: No
Woman Owned: No
Award Charts
Award Listing
-
ADHD Therapeutic: PD2005 DA Transport Inhibitor
Amount: $1,096,801.00DESCRIPTION (provided by applicant): SBIR Phase 1 preclinical studies demonstrate the efficacy of our proprietary compound, PD2005, for treating Attention Deficit/Hyperactivity Disorder (ADHD). P ...
SBIRPhase II2011Department of Health and Human Services National Institutes of Health -
Y2 and Y4 Agonists in Obesity
Amount: $247,153.00DESCRIPTION (provided by applicant): The purpose of the proposed studies is to assess the feasibility of developing a novel Neuropeptide Y (NPY) obesity treatment. Extensive preclinical and clinical s ...
SBIRPhase I2010Department of Health and Human Services National Institutes of Health -
PD2024: A Peripherally Active TNFalpha inhibitor for the treatment of Obesity
Amount: $272,082.00DESCRIPTION (provided by applicant): The purpose of the proposed SBIR Phase 1 feasibility study is to assess the efficacy of our lead tumor necrosis factor- alpha (TNF1) inhibitor for the treatment of ...
SBIRPhase I2010Department of Health and Human Services National Institutes of Health -
Small Molecule targeting of NADPH oxidase in neutrophils
Amount: $318,654.00DESCRIPTION (provided by applicant): Acute lung injury (ALI) and Acute Respiratory Distress Syndrome (ARDS) are characterized by a rapid and severe respiratory failure, arising after clinical events i ...
STTRPhase I2010Department of Health and Human Services National Institutes of Health -
Betahistine: Novel Therapeutic in Attention Deficit Hyperactivity Disorder
Amount: $469,495.00DESCRIPTION (provided by applicant): Satiety Solutions, is developing a novel histamine agonist, betahistine, as a treatment for attention-deficit, hyperactivity disorder (ADHD). Betahistine is a hist ...
SBIRPhase I2009Department of Health and Human Services National Institutes of Health -
Selective DAT Inhbitor for the Treatment of Obesity
Amount: $212,981.00DESCRIPTION (provided by applicant): The purpose of the present SBIR Phase 1 feasibility study is to assess the efficacy of our selective dopamine transport (DAT) inhibitor, PD2007, for the treatment ...
SBIRPhase I2008Department of Health and Human Services National Institutes of Health -
A Human Antibody as an Immunotherapy for Cocaine Abuse
Amount: $911,120.00DESCRIPTION (provided by applicant): Despite an understanding of the pharmacological basis of cocaine abuse no effective pharmacotherapy has been developed, suggesting that pharmacotherapy may be impr ...
SBIRPhase II2007Department of Health and Human Services National Institutes of Health -
Thiothalidomides as neuroprotectant drugs for PD.
Amount: $358,216.00DESCRIPTION (provided by applicant): The goal of this Phase 1 SBIR proposal is to identify drug candidate(s) from a tumor necrosis factor a (TNF-a) inhibiting library of compounds for treating Parkins ...
SBIRPhase I2007Department of Health and Human Services National Institutes of Health -
Selective DAT Inhibitor for Treatment of ADHD
Amount: $228,706.00DESCRIPTION (provided by applicant): Currently, the non-selective dopamine (DA) transport inhibitors methylphenidate and d- amphetamine are the only approved first line treatments for Attention Defici ...
SBIRPhase I2007Department of Health and Human Services National Institutes of Health -
COCAINE THERAPEUTIC: PD2007
Amount: $242,814.00DESCRIPTION (provided by applicant): Extensive research suggests that cocaine's abuse potential is associated with direct binding and inhibition of the DA transporter. Our proprietary compound, PD2007 ...
SBIRPhase I2007Department of Health and Human Services National Institutes of Health
